<DOC>
	<DOCNO>NCT01785472</DOCNO>
	<brief_summary>This study ass efficacy safety multiple dos LCZ696 compare olmesartan Asian patient essential hypertension</brief_summary>
	<brief_title>Efficacy Safety LCZ696 Comparison Olmesartan Asian Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients mildtomoderate hypertension , untreated currently take antihypertensive therapy . Treated patient ( use antihypertensive treatment within 4 week prior Visit 1 ) must msSBP≥150 mmHg &lt; 180 mmHg randomization visit ( Visit 201 ) msSBP≥140 mmHg &lt; 180 mmHg visit immediately precede Visit 201 ( Visit 102 103 ) . Untreated patient ( newly diagnose essential hypertension history hypertension take antihypertensive drug least 4 week prior Visit 1 ) must msSBP≥150 mmHg &lt; 180 mmHg Visit 1 Visit 201 . Patients must absolute difference ≤15 mmHg msSBP Visit 201 immediately precede visit . Patients severe hypertension ( msDBP ≥110 mmHg msSBP ≥180 mmHg ) . History angioedema , drugrelated otherwise , report patient . History evidence secondary form hypertension , include limited following : renal parenchymal hypertension , renovascular hypertension ( unilateral bilateral renal artery stenosis ) , coarctation aorta , primary hyperaldosteronism , Cushing 's disease , pheochromocytoma , polycystic kidney disease , druginduced hypertension . Patients previously enter LCZ696 study randomize enrolled active drug treatment epoch . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>LCZ696</keyword>
</DOC>